Doximity GPT: The Full Story of DoxGPT, Doximity Ask, and the Rise of the AI Doctor Assistant

Doximity GPT

In early 2023, only weeks after ChatGPT took the internet by storm, a company best known as “LinkedIn for doctors” opened a free chatbot that wrote insurance appeal letters. Three years later, that tool has a new name, a peer review program with more than 10,000 physicians, a drug-dosing safety check, and a deal to show UpToDate content. Doximity GPT, also called DoxGPT and now called Doximity Ask, has become one of the most widely used AI tools among US clinicians. This guide covers where it came from, what it does, how accurate it claims to be, what it costs, and what doctors should keep in mind before using it.

Quick Overview

What Is Doximity?

To understand the tool, it helps to know the company behind it. Doximity is an online professional network for US medical professionals. It was co-founded by Jeff Tangney, who earlier co-founded the drug reference app Epocrates, and went public in 2021.

Doximity says it has more than 3 million registered members, including about 85 percent of US physicians and about two-thirds of nurse practitioners and physician assistants. Clinicians use it for news, secure faxing, telehealth calls through its Dialer app, and professional profiles. The company makes most of its money from pharmaceutical marketing and hiring services sold to health systems, which is why its core tools are free to clinicians.

For fiscal year 2026, which ended March 31, 2026, Doximity reported revenue of $645 million, up 13 percent from the year before.

The History of Doximity GPT

2023: DocsGPT Opens in Beta

Doximity first launched its AI assistant in early 2023 as DocsGPT, an open beta built with OpenAI’s ChatGPT and tuned on healthcare writing. Its first job was paperwork. Doctors could ask it to draft:

• Prior authorization requests
• Insurance claim denial appeals
• Certificates of medical necessity
• Referral letters
• Post-procedure instruction sheets
• Letters of recommendation for medical students

A key feature was the link to Doximity’s fax service. A doctor could draft a letter, review and edit it, then fax it straight to an insurer. Early versions warned users not to include patient identifiers in prompts and labeled every result “PLEASE EDIT FOR ACCURACY BEFORE SENDING.”

2024 to 2025: A New Name and a Bigger Role

The tool was renamed Doximity GPT, often shortened to DoxGPT. Over time, it grew from a letter writer into a clinical question answering tool. Doximity added dictation, file uploads, and saved templates.

Mid-2025: The Pathway Acquisition

In summer 2025, Doximity bought Pathway, a clinical AI and medical reference company, for $63 million. Pathway brought a knowledge graph built from peer-reviewed evidence, with information on drug interactions and the strength of evidence behind recommendations.

In September 2025, Doximity said Pathway’s model and medical data were built into its GPT on web and mobile. The company also added “Instant Answers” for more than 3,200 drug monographs, which show dosing, interactions, and side effects as soon as a user types the first few letters of a drug name.

Late 2025: PeerCheck

Doximity then launched PeerCheck, a program in which physicians review AI-generated answers for accuracy, strength of evidence, and bias. By early 2026, more than 10,000 physicians had taken part, completing tens of thousands of reviews. Cardiologist and researcher Dr. Eric Topol and former US Surgeon General Dr. Regina Benjamin serve as co-editors-in-chief. Reviewed answers link to the profiles of the physicians who checked them.

May 2026: Doximity Ask and the Clinical AI Suite

On May 7, 2026, Doximity announced its Clinical AI Suite and renamed DoxGPT as Doximity Ask. The suite has three parts:

• Ask: The clinical AI assistant, formerly DoxGPT.
• Scribe: An AI tool that writes visit notes from patient conversations.
• Dialer: Doximity’s calling, video, and texting tool for patient visits.

The old doxgpt.com address now redirects to Doximity, but many doctors still call the tool DoxGPT.

July 2026: The NOHARM Benchmark

In July 2026, Doximity highlighted results from NOHARM, a clinical AI safety benchmark created by ARISE, a research group led by physicians from Stanford and Harvard medical schools. The project tested many AI systems on simulated patient cases across 10 specialties. Doximity said its tool ranked first among the systems evaluated on the study’s real-world clinical sample, and in its earnings remarks reported an error rate of 4.8 percent, the lowest among US models. These figures come from Doximity’s own reporting of the study, so readers who want the full picture should review the paper itself, posted on arXiv.

October 2026: UpToDate and DoseCheck

On October 20, 2026, Doximity and Wolters Kluwer announced a partnership to bring UpToDate content into Doximity Ask. Clinicians at health systems that use both services are set to see UpToDate-based answers inside Ask, with the rollout beginning in the weeks after the announcement.

On October 29, 2026, Doximity launched DoseCheck, a free safety layer for every Ask user. DoseCheck compares each AI-generated dosing claim with a structured drug database based on FDA labeling and professional guidelines. Instead of relying on another AI model, it uses fixed rules.

Doximity GPT Healthcare Features

Here is what the current version can do, based on Doximity’s descriptions.

Clinical Questions

• Instant Mode for quick answers
• Thinking Mode for complex cases that need deeper reasoning
• Inline citations that point to sources
• Full-text PDF access to articles from more than 2,000 peer-reviewed journals
• Drug monographs grounded in FDA labeling, covering dosing, interactions, and contraindications

Documents and Letters

• Prior authorization letters
• Insurance appeal letters
• Patient education materials
• Patient messages and follow-up texts
• Discharge summaries and progress note templates

File Uploads

Users can upload lab reports, imaging summaries, research papers, notes, or patient letters. The tool can pull out key findings, treatments, or medications.

Saved Preferences

A “Projects” feature lets clinicians save preferred journals, references, charting formats, and letter styles, so the assistant follows the same style each time.

Dictation

Doctors can speak their questions or requests on web and mobile instead of typing.

Fax and Messaging

Letters can be faxed to insurers, and patient education materials can be sent by secure text, all inside the Doximity platform.

Is Doximity GPT HIPAA Compliant?

Doximity describes its AI assistant as HIPAA-compliant and “secure by default.” The company says prompts and responses are private to each clinician and that data is encrypted both in transit and at rest.

There are a few points worth noting:

• In 2023, the beta asked users not to include patient identifiers in prompts. Later versions are marketed as fully HIPAA-compliant.
• Public marketing pages do not clearly describe a business associate agreement (BAA) for individual users.
• Hospitals and clinics often have their own rules about AI tools.

Before entering identifiable patient information, clinicians should check their employer’s policy and confirm the tool’s current terms.

Who Can Use It and What It Costs

Doximity says its AI tools are free for verified US physicians, nurse practitioners, physician assistants, and medical students with a Doximity account. Doximity markets Ask most heavily to physicians.

Health systems can also buy enterprise access to the Clinical AI Suite. By August 2026, Doximity reported 165 signed health system AI clients, including 8 hospitals on the U.S. News Honor Roll. Earlier in 2026, it said more than 250,000 prescribers had access through enterprise deals.

How Doximity Makes Money From AI

Since clinicians use Ask for free, Doximity earns AI revenue in two main ways:

1. Enterprise contracts with health systems.
2. Sponsored content in AI search, sold to pharmaceutical companies. Doximity began selling AI search placements in late April 2026 and said it expected most of that contracted revenue to show up later in fiscal 2027.

Doctors should keep this model in mind. Pharmaceutical companies pay to reach clinicians on Doximity, so it helps to notice which content is sponsored.

How Many Clinicians Use It?

Doximity has shared several usage numbers in its earnings reports:

The company has also said that in a comparison with more than 1,300 physicians, DoxGPT was chosen as the best answer 61 percent of the time when a preference was stated, versus 26 percent for OpenEvidence. Like the NOHARM figures, this comes from the company.

Doximity Ask vs. OpenEvidence

OpenEvidence is Doximity’s main rival in clinical AI search. Both offer free AI answers to US clinicians, both cite medical literature, and both earn money mainly from advertising and partnerships.

The rivalry has turned into a legal fight:

• In June 2025, OpenEvidence sued Doximity, alleging that it had tried to reverse engineer OpenEvidence’s system.
• In September 2025, Doximity countersued, alleging that OpenEvidence had spread false information about it.

Both cases were ongoing as of the latest public reports. Doximity CEO Jeff Tangney told investors in February 2026, “We believe we’ll win the AI market here in 2026.”

Doximity GPT as an AI Doctor: What It Can and Cannot Do

People sometimes search for an “AI doctor,” but tools like this one are not doctors. They are assistants built for licensed clinicians. Here is a clear view of the line:

What it can help with:

• Drafting letters and paperwork faster
• Summarizing research and guidelines
• Looking up drug information quickly
• Creating patient-friendly explanations
• Writing visit notes through Scribe

What it cannot do:

• Examine a patient
• Replace clinical judgment
• Take legal or professional responsibility for care
• Guarantee that every answer is correct

The tool is not designed for patients to diagnose themselves. Anyone with a health concern should speak with a licensed clinician.

Accuracy and Safety Concerns

Even with peer review and dosing checks, AI tools can make mistakes. Doximity’s own testing found how risky dosing errors can be. When it tested nine widely used AI models with more than 8,000 dosing questions, at least 2.3 percent of the dosing claims were wrong, and 43.8 percent of those errors were serious or potentially lethal. Doximity says DoseCheck raises dosing accuracy in Ask to more than 99 percent.

Common problem areas for AI dosing answers include:

• Newly approved drugs that are missing from older training data
• Failing to adjust doses for kidney function, age, or weight
• Errors in units or decimal places
• Mixing up drugs with similar names

Good practices for clinicians:

1. Check the citations. Open the source and confirm it supports the answer.
2. Verify dosing. Cross-check doses with your own drug reference or pharmacist.
3. Edit every letter. Make sure each letter matches the patient’s real history.
4. Protect privacy. Follow your organization’s rules on patient data.
5. Stay skeptical of marketing claims. Company-reported benchmarks are useful, but independent studies carry more weight.

Step by Step: How to Start Using Doximity Ask

1. Create or sign in to a Doximity account on the web or the mobile app.
2. Verify your credentials as a US clinician or medical student.
3. Open Ask from the Doximity app menu, the desktop app, or doximity.com.
4. Choose a mode. Use Instant Mode for quick lookups or Thinking Mode for complex cases.
5. Type, dictate, or upload your question or document.
6. Review the answer and its sources before acting on it.
7. Save templates in Projects for letters or notes you write often.

Doximity has also run live training sessions for its Clinical AI Suite. For the company’s own walkthrough of the new tools, see Doximity’s introduction to the Clinical AI Suite.

Pros and Cons

Pros

• Free for verified US clinicians
• Built into a platform most US physicians already use
• Saves time on prior authorizations and appeal letters
• Physician review through PeerCheck
• Rule-based dosing checks through DoseCheck
• Full-text access to many journal articles
• Links with fax, calling, and scribe tools

Cons

• Available mainly to US clinicians
• Many accuracy claims come from the company itself
• HIPAA details, such as BAAs, are not clearly spelled out for individual users
• Pharmaceutical sponsorship may shape some content
• UpToDate access depends on whether your health system licenses both services

Frequently Asked Questions

Is DoxGPT the same as Doximity Ask? Yes. Doximity renamed DoxGPT to Doximity Ask in May 2026.

Is it free? Yes, for verified US clinicians with a Doximity account. Health systems can buy enterprise versions.

Which AI model does it use? The original DocsGPT was built with OpenAI’s ChatGPT. Today, Doximity combines large language models with Pathway’s knowledge graph, PeerCheck reviews, and DoseCheck. It does not publicly list every model it uses.

Can patients use it? It is built for clinicians. Patients should talk with their own doctor about health questions.

Is it available outside the United States? Doximity’s network focuses on US clinicians, so access outside the US is limited.

Does it include UpToDate? Through an October 2026 partnership, clinicians at health systems that use both Doximity and UpToDate are set to see UpToDate-based answers in Ask.

Where Clinical AI Goes From Here

Doximity GPT began as a simple letter writer and has grown into a full clinical AI suite with peer review, dosing checks, and links to trusted references. For busy US clinicians, it offers a free way to cut paperwork and find answers faster. Still, the tool works best as an assistant, not an authority. Doctors who check sources, verify doses, and follow their organization’s privacy rules will get the most from it while keeping patients safe.

Key Takeaways

• Doximity GPT launched in 2023 as DocsGPT, a free ChatGPT-based tool for medical paperwork.
• It was later called DoxGPT and was renamed Doximity Ask in May 2026.
• Ask is part of Doximity’s Clinical AI Suite, with Scribe and Dialer.
• Doximity bought Pathway for $63 million in 2025 to power its clinical answers.
• PeerCheck uses more than 10,000 physician reviewers; DoseCheck verifies dosing claims with fixed rules.
• An October 2026 deal brings UpToDate content to Ask for clinicians at health systems that use both services.
• The tool is free for verified US clinicians, and Doximity earns AI revenue from health systems and pharma.
• Accuracy claims mostly come from Doximity, so clinicians should verify answers before acting.